Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioLineRx Ltd.
Keeping Track: Terliprez, Sotyktu Keep Up US FDA’s Novel Approvals Pace; Submissions By Pfizer, Chiesi And BioLineRx
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BioLineRx's Phase IIa study of Keytruda/motixafortide/chemo showed improvements in overall and progression-free survival compared with historical data.
The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Agalimmune Limited
- Agalimmune Ltd.
- Agalimmune Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.